This Article Full Text Full Text (PDF) All Versions of this Article: 111/9/1106    most recent 01.CIR.0000157146.86758.BCv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Weintraub, W. S. Articles by Pitt, B. Search for Related Content PubMed PubMed Citation Articles by Weintraub, W. S. Articles by Pitt, B. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Heart Attack Heart Failure Hazardous Substances DB SPIRONOLACTONE Related Collections Health policy and outcome research Congestive Cardiovascular Pharmacology Other Treatment Acute myocardial infarction Related Article

(Circulation. 2005;111:1106-1113.)
© 2005 American Heart Association, Inc.

Health Services and Outcomes Research

Cost-Effectiveness of Eplerenone Compared With Placebo in Patients With Myocardial Infarction Complicated by Left Ventricular Dysfunction and Heart Failure

William S. Weintraub, MD; Zefeng Zhang, MD, PhD; Elizabeth M. Mahoney, ScD; Paul Kolm, PhD; John A. Spertus, MD, MPH; Jaime Caro, MD; Jack Ishak, MSc; Robert Goldberg, PhD; Joseph Tooley, PharmD, MBA; Richard Willke, PhD; Bertram Pitt, MD

From Emory University, Atlanta, Ga (W.S.W., Z.Z., P.K.); New England Research Institutes, Watertown, Mass (E.M.M.); Mid America Heart Institute, Kansas City, Mo (J.A.S.); Caro Research, Inc., Boston, Mass (J.C., J.I.); University of Massachusetts, Worcester (R.G.); Prudential Equity Group, Deerfield, Ill (J.T.); Pfizer, Inc, New York, NY (R.W.); and University of Michigan, Ann Arbor (B.P.).

Correspondence to William S. Weintraub, MD, Professor of Medicine, Emory University, 1256 Briarcliff Rd, Suite 1N, Atlanta, GA 30306. E-mail wweintr{at}emory.edu

Received July 8, 2004; revision received November 14, 2004; accepted November 24, 2004.

Background— In the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS), aldosterone blockade with eplerenone decreased mortality in patients with left ventricular systolic dysfunction and heart failure after acute myocardial infarction. The present study was performed to evaluate the cost-effectiveness of eplerenone compared with placebo in these patients.

Methods and Results— A total of 6632 patients with left ventricular systolic dysfunction and heart failure after acute myocardial infarction were randomized to eplerenone or placebo and followed up for a mean of 16 months. The coprimary end points were all-cause mortality and the composite of cardiovascular mortality/cardiovascular hospitalization. The evaluation of resource use included hospitalizations, outpatient services, and medications. Eplerenone was priced at the average wholesale price, $3.60 per day. Survival beyond the trial period was estimated from data from the Framingham Heart Study, the Saskatchewan Health database, and the Worcester Heart Attack Registry. The incremental cost-effectiveness of eplerenone in cost per life-year and quality-adjusted life-year gained compared with placebo was estimated. The number of life-years gained with eplerenone was 0.1014 based on Framingham (95% CI, 0.0306 to 0.1740), 0.0636 with Saskatchewan (95% CI, 0.0229 to 0.1038), and 0.1337 with Worcester (95% CI, 0.0438 to 0.2252) data. Cost was $1391 higher over the trial period in the eplerenone arm (95% CI, 656 to 2165) because of drug cost. The incremental cost-effectiveness ratio was $13 718 per life-year gained with Framingham (96.7% under $50 000 per life-year gained), $21 876 with Saskatchewan, and $10 402 with Worcester.

Conclusions— Eplerenone compared with placebo in the treatment of heart failure after acute myocardial infarction is effective in reducing mortality and is cost-effective in increasing years of life by commonly used criteria.

Key Words: cost-benefit analysis • heart failure • myocardial infarction

Related Article:

Issue Highlights
Circulation 2005 111: 1093. [Extract] [Full Text]

This article has been cited by other articles:

				M. M. Shafiq and A. B. Miller Blocking aldosterone in heart failure Therapeutic Advances in Cardiovascular Disease, October 1, 2009; 3(5): 379 - 385. [Abstract] [PDF]

				L. Marcoff, Z. Zhang, W. Zhang, E. Ewen, C. Jurkovitz, P. Leguet, P. Kolm, and W. S. Weintraub Cost effectiveness of enoxaparin in acute ST-segment elevation myocardial infarction: the ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction 25) study. J. Am. Coll. Cardiol., September 29, 2009; 54(14): 1271 - 1279. [Abstract] [Full Text] [PDF]

				P. S. Chan, G. Soto, P. G. Jones, B. K. Nallamothu, Z. Zhang, W. S. Weintraub, and J. A. Spertus Patient Health Status and Costs in Heart Failure: Insights From the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) Circulation, January 27, 2009; 119(3): 398 - 407. [Abstract] [Full Text] [PDF]

				C. D Moyer and P. B Berger Adjunctive treatment with eplerenone reduced 30 day all cause mortality in acute myocardial infarction Evid. Based Med., February 1, 2006; 11(1): 14 - 14. [Full Text] [PDF]

				W. S. Weintraub Implications of the Multicenter Automatic Defibrillator Implantation Trial-II Ann Intern Med, January 3, 2006; 144(1): 65 - 65. [Full Text] [PDF]

				T. R. Marcy and T. L. Ripley Aldosterone antagonists in the treatment of heart failure Am. J. Health Syst. Pharm., January 1, 2006; 63(1): 49 - 58. [Abstract] [Full Text] [PDF]

				H. M. Krumholz The Year in Epidemiology, Health Services, and Outcomes Research J. Am. Coll. Cardiol., October 4, 2005; 46(7): 1362 - 1370. [Full Text] [PDF]

				E. C. Stecker and J. H. McAnulty Letter Regarding Article by Weintraub et al, "Cost-Effectiveness of Eplerenone Compared With Placebo in Patients With Myocardial Infarction Complicated by Left Ventricular Dysfunction and Heart Failure" Circulation, August 2, 2005; 112(5): e74 - e74. [Full Text] [PDF]